Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Doxorubicin × 1 year × Clear all

Phase

Status

Active not recruiting 97 Recruiting 83 Completed 49 Not yet recruiting 15 Terminated 9 Suspended 4 Withdrawn 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 16 Specimen Handling 13 pembrolizumab 12 Cyclophosphamide 9 Biopsy 9 fludarabine 8 Radiotherapy 7 Carboplatin 6 Paclitaxel 5 Nivolumab 5 fludarabine phosphate 4 atezolizumab 4 X-Rays 4 Phantoms, Imaging 4 Cisplatin 4 venetoclax 3 niraparib 3 durvalumab 3 decitabine and cedazuridine drug combination 3 cemiplimab 3 aldesleukin 3 Standard of Care 3 Radiosurgery 3 Radiation 3 Practice Guidelines as Topic 3 Injections 3 Fluorouracil 3 Capecitabine 3 Blood Specimen Collection 3 Bendamustine Hydrochloride 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06829199 2026-02-19

MK-5890-003

Merck Sharp & Dohme LLC

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡